Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px
Organisation › Details

Akamis Bio Ltd.

Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis Bio has a growing pipeline of T-SIGn® therapeutics anchored by its two clinical-stage programs, NG-350A (an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody) and NG-641 (a stromal-targeted tumor gene therapy leveraging a viral vector encoding a FAP-CD3 bispecific antibody, CXCL-9, CXCL-10 & interferon alpha). NG-350A and NG-641 are both being investigated in ongoing Phase 1 clinical studies in patients with metastatic or advanced epithelial tumors. In addition to internal pipeline development efforts, Akamis Bio has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI). *

 

Period Start 2023-01-05 renamed
  Group Akamis Bio (Group)
  Predecessor PsiOxus Therapeutics Ltd.
Product Industry oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy)
Persons Person Davis, Howard E. (PsiOxus 202208– CEO based in Boston area before Atlas Venture + Third Harmonic Bio + Flagship)
  Person 2 Paoletti, Paolo (GammaDelta Therapeutics 201705– CEO before Kesios Therapeutics CEO + GSK)
     
Region Region Abingdon, Oxfordshire
  Country United Kingdom (GB)
  Street Barton Lane
Abingdon Science Park, The Quadrant, 4-10
  City OX14 3YS Abingdon, Oxfordshire
  Tel +44-1235-835328
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
     
    * Document for »About Section«: Akamis Bio Ltd.. (1/5/23). "Press Release: Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics". Cambridge, MA & Oxford.
     
   
Record changed: 2023-07-10

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Akamis Bio (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px




» top